BACKGROUND: Steroid-induced adverse effects including suppression of humoral immunity should be considered in steroid-dependent severe asthma. Only a few studies have determined the exact steroid dose that could potentially suppress humoral immunity in asthmatics. METHODS: Randomly selected 100 adult asthmatics treated withinhaled beclomethasone dipropionate (BDP) were classified into three groups based on the dose of steroid to determine the serum IgG, IgA and IgM levels by radioimmunoassay. Relationships between serum immunoglobulin levels and the daily dose and duration of oral prednisolone (PSL) therapy were examined. RESULTS: None of the patients on inhaled corticosteroid alone had hypogammaglobulinemia. Patients on oral PSL at a dose >12.5 mg/day for at least 1 year had low serum IgG. There was no significant correlation between the duration of oral PSL therapy and serum IgG. CONCLUSIONS:Oral PSL can potentially suppress humoral immunity in severe asthma. In asthmatics, hypogammaglobulinemia could develop in those on a daily dose of PSL >12.5 mg, but is independent of the duration of such treatment. No suppression of humoral immunity was noted on inhaled corticosteroid therapy alone, either at low or high dose. Copyright 2002 S. Karger AG, Basel
RCT Entities:
BACKGROUND:Steroid-induced adverse effects including suppression of humoral immunity should be considered in steroid-dependent severe asthma. Only a few studies have determined the exact steroid dose that could potentially suppress humoral immunity in asthmatics. METHODS: Randomly selected 100 adult asthmatics treated with inhaled beclomethasone dipropionate (BDP) were classified into three groups based on the dose of steroid to determine the serum IgG, IgA and IgM levels by radioimmunoassay. Relationships between serum immunoglobulin levels and the daily dose and duration of oral prednisolone (PSL) therapy were examined. RESULTS: None of the patients on inhaled corticosteroid alone had hypogammaglobulinemia. Patients on oral PSL at a dose >12.5 mg/day for at least 1 year had low serum IgG. There was no significant correlation between the duration of oral PSL therapy and serum IgG. CONCLUSIONS: Oral PSL can potentially suppress humoral immunity in severe asthma. In asthmatics, hypogammaglobulinemia could develop in those on a daily dose of PSL >12.5 mg, but is independent of the duration of such treatment. No suppression of humoral immunity was noted on inhaled corticosteroid therapy alone, either at low or high dose. Copyright 2002 S. Karger AG, Basel
Authors: Are M Holm; Siw L Andreassen; Vivi Lycke Christensen; Johny Kongerud; Øystein Almås; Henrik Auråen; Anne H Henriksen; Ingeborg S Aaberge; Olav Klingenberg; Tone Rustøen Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-04-16
Authors: Sai S Duraisingham; Matthew Buckland; John Dempster; Lorena Lorenzo; Sofia Grigoriadou; Hilary J Longhurst Journal: PLoS One Date: 2014-06-27 Impact factor: 3.240
Authors: Juthaporn Cowan; Logan Gaudet; Sunita Mulpuru; Vicente Corrales-Medina; Steven Hawken; Chris Cameron; Shawn D Aaron; D William Cameron Journal: PLoS One Date: 2015-11-11 Impact factor: 3.240
Authors: Andrej A Petrov; Russell S Traister; Maria M Crespo; Fernanda P Silveira; Maylene Xie; Kara Coffey; Christopher R Ensor; Douglass Landsittel; Joseph M Pilewski Journal: Transplant Direct Date: 2018-07-12